Funding

Health Care Startup Aurenar Scores $5.7M in Seed Funding

Jul 29, 2026 | By Devin Jacobs

SUMMARY

Aurenar has raised $5.7 million in Seed funding co-led by the Go Red for Women Venture Fund™ and Solas BioVentures.
Aurenar develops non-invasive neuromodulation technology to improve care for intensive care and stroke patients.
The company will use the funding to advance its device development, prepare for clinical trials, complete FDA testing, and support regulatory approvals.

Aurenar, a healthcare technology company developing non-invasive neuromodulation solutions for intensive care patients, has raised $5.7 million in an oversubscribed Seed funding round.

The round was co-led by the Go Red for Women Venture Fund™, part of American Heart Association Ventures™, and Solas BioVentures, with participation from BJC Health and Kaleida Capital.

The funding will support device development, clinical trial preparation, verification and validation testing, and regulatory submissions to the U.S. Food and Drug Administration (FDA).

Funding Snapshot

Metric	Details
Fundraise Amount	$5.7 Million
Valuation	Undisclosed
Company	Aurenar
Sector	HealthTech / Medical Devices
Headquarters	United States

RECOMMENDED FOR YOU

Funding

ConnectWise To Acquire zofiQ

Startuprise

Jan 21, 2026

Funding

Recess Raises $30M in Series B Funding

Startuprise

Nov 6, 2025

Funding

[Funding alert] Cambridge-based Ceretype Neuromedicine Secures its Second Round of Seed Funding

Devin Jacobs

Jan 6, 2024

About Aurenar

Founded by Eric Leuthardt, Aurenar is developing non-invasive neuromodulation technology aimed at improving outcomes for critically ill patients. The company’s flagship V-Link™ platform delivers transauricular vagus nerve stimulation (taVNS) to influence the body’s inflammatory response and reduce secondary injuries associated with severe medical conditions.

Initially focused on stroke and neurocritical-care applications, Aurenar’s technology has the potential to expand into multiple high-acuity healthcare areas where inflammation contributes to poor patient outcomes.

Core offerings include:

Non-invasive neuromodulation platform.
Single-use ICU-focused medical devices.
Wireless vagus nerve stimulation technology.
Inflammation management solutions for critical care.

Core Technologies / Products / Services

Capability/Product	Application/Use Case
V-Link™ Platform	Non-invasive neuromodulation for ICU patients
taVNS Technology	Regulating inflammatory responses
Wireless Medical Device	Simplifying ICU deployment and adoption
Neurocritical Care Solutions	Supporting stroke and critical illness recovery

Leadership Comments

"We are excited to support Aurenar because stroke is a major cause of mortality and long-term disability in women, who face a disproportionately higher prevalence of subarachnoid hemorrhage. Their V-Link product promises to offer a pathway to improve recovery for all patients and especially for women who often experience higher rates of post-stroke complications," said Tracy Warren, Sr. Managing Director, Go Red for Women Venture Fund, part of the American Heart Association Ventures family of funds.

"This seed close marks a pivotal moment for Aurenar," said Dr. Leuthardt, Founder and Chief Executive Officer of Aurenar and a professor of neurosurgery at WashU Medicine. "With the support of the Go Red for Women Venture Fund, Solas BioVentures and our broader investor group, we are positioned to advance from early-stage neurotechnology to a pivotal-trial-ready company.

"At WashU, we are reinforcing pathways that convert bold scientific ideas into real-world solutions," said Doug Frantz, PhD, Vice Chancellor for Innovation and Commercialization, Washington University. "This neuromodulation platform is yet another example of the strength of WashU's innovation ecosystem, and Dr. Leuthardt's progress with Aurenar is bringing us closer to delivering meaningful advances to some of our most critically ill patients."